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Nationwide, clinical trial enrollment is very low for eligible patients, averaging 3-5%,
and this has a signi cant impact on both patient’s health as well as medical research
outcomes. The current paradigm is more focused enrollment of historically
underrepresented groups, however, additional research is directed at potential clinic
based solutions for how to more effectively recruit all patients. Studies are showing
improved clinical ef ciency when using medical scribes (Gidwani et al., 2017) as well
as using arti cial intelligence software to screen for eligible patients (Calaprice-Whitty
el al., 2019). Jefferson’s Otolaryngology department has recently transitioned to fulltime scribe coverage for the Head and Neck cancer clinics in addition to increased
patient volume over the past few years and is interested in determining what methods,
if any, may be effective ways to enroll more patients on clinical trials. We are
interested in exploring issues with recruitment from the patient and clinician
perspectives and guring out how to increase Jefferson’s rate of enrollment into
clinical trials.

Introduction

Objectives
& Hypothesis
• Research Question
– What are possible barriers to enrollment from the
perspective of both surgical oncologists and their
patients?

• Hypothesis
– Use of an Epic SmartPhrase for evaluation of common
barriers to clinical trial enrollment will allow further
documentation for explanations of ineligibility or refusal
to enroll.
– Additionally, we anticipate that lowered wait times will
lead to increased patient enrollment into clinical trials

Approach & Results
• Study design: Prospective Observational
• Population / study sample: Patients who were eligible for
any of the 8 clinical trials for H&N cancer offered at
Jefferson between August and December 2020 were
identified.
• Intervention: Pending, but a video to be played in the
clinic waiting room with basic information regarding
clinical trial enrollment.
• Data source and collection: Epic EMR and REDCap
• Rationale for Approach: We utilized an Epic EMR phrase
to capture if a trial was offered or not and why, whether a
patient refused enrollment and why, and patient wait time.

Approach & Results
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During the 4 month period, the clinic saw 45 new patients with a
cancer diagnosis and the EMR SmartPhrase was used 32 times.
For those offered a trial, 38.5% agreed to enroll and 15.3%
deferred to make a nal decision at a later appointment. Of
patients that were eligible for a trial but declined, 60% were due
to concerns about clinical trial enrollment and 40% because of
general disinterest. Reasons for ineligibility were more dif cult to
track in the group where SmartPhrase was not used because the
providers’ thought processes were not declared. We will present
average wait time data at a later time.

Approach & Results
August 2020-December 2020
Patients offered 13
trial
Said Yes

6

Deferred

2

Said No

5

Nivo + IDO trial and ETIP trial
were the two most commonly
enrolled trials

Conclusions
• Our preliminary data shows an increased rate of patient
enrollment (38.5%) into clinical trials compared to the
national average (3-5%)
• Likely this percentage will fall with increased patient
volume but could be lower due to concerns about COVID
• Standardizing clinic note templates with the Epic
SmartPhrase likely leads to increased patient enrollment
• Consistent usage of SmartPhrase was complicated by
scribe and departmental turnover during the 4 month
period
• We are awaiting data regarding patient wait times, which
may pose a major barrier in enrollment

Future Directions
We are currently designing the intervention, which is a
video with basic information and FAQ’s regarding clinical
trials, featuring the surgical and medical oncologists as well
as the clinical trial coordinator for the cancer center. This
will be shown in the waiting room of the clinic on repeat so
that new patients are more comfortable with the topic of
clinical trials before they are approached about it by the
surgeons. By time of implementation, we will have
approximately 6 months of pre-intervention data.
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